Vector Labs Ab04634-3.0 Anti-PD-1 [RMP1-30], Mouse IgG2b, kappa (100 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: RMP1-30
Synonyms: CD279; mPD-1; Protein PD-1; Programmed cell death protein 1
Amount: 100 μg
Application Codes Clone: Blocking; in vivo; in vitro; FC; FACS
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG2b
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This chimeric mouse antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody is specific for mouse PD-1.
Application Notes: The original version of this antibody (rat IgG2b) was used to investigate PD-1 signaling pathways in the context of allergic sensitization and challenge in mice. Specifically, it was used to determine how PD-1 blockade affects airway reactivity and immune responses (Matsumoto et al., 2004; PMID: 14764726). The original antibody was used successfully for blocking the PD-1 pathway in combination with ex vivo TKD/IL-2-stimulated NK cells in preclinical models of glioblastoma and lung cancer. It was found that this combination therapy significantly enhanced the cytotoxic activity of NK cells compared to monotherapy. The treatment resulted in improved overall survival, massive infiltration of tumors by CD8⁺ cytotoxic lymphocytes and NK1.1 cells, and a reduction of PD-1⁺ immune cells in the tumor microenvironment. Additionally, the combined therapy maintained its anti-tumor effects even after discontinuation, suggesting long-term benefits and highlighting the potential of this combined immunotherapeutic approach (Shevtsov et al., 2019; PMID: 30967859). The original version of this antibody was used successfully in an in vitro blocking assay on EL4 cells. It was also used for FC analysis and was found to stain the cells with medium intensity compared to the other tested antibodies (Polesso et al., 2021; PMID: 33684223). This antibody was also used for the FC and FACS analyses on tumor-infiltrating immune cells (TIIs) (Yokota et al., 2021; PMID: 34355173) and murine B16-F10 and YUMM melanoma cells and T-cells subsets (Martins et al., 2022; PMID: 35864188). This antibody was tested for its binding affinity to Jurkat cells expressing mouse PD-1. It exhibited intermediate avidity for PD-1 and showed limited capability to reverse PD-1-mediated T-cell inhibition compared to other tested antibodies. It demonstrated partial epitope blocking against itself and another PD-1 monoclonal antibody, indicating its suitability for specific experimental conditions requiring PD-1 staining alongside functional assessments (Bu et al., 2022; PMID: 35925787).

Product Class:	Purified
Clone ID:	RMP1-30
Synonyms:	CD279; mPD-1; Protein PD-1; Programmed cell death protein 1
Amount:	100 μg
Application Codes Clone:	Blocking; in vivo; in vitro; FC; FACS
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG2b
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This chimeric mouse antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody is specific for mouse PD-1.
Application Notes:	The original version of this antibody (rat IgG2b) was used to investigate PD-1 signaling pathways in the context of allergic sensitization and challenge in mice. Specifically, it was used to determine how PD-1 blockade affects airway reactivity and immune responses (Matsumoto et al., 2004; PMID: 14764726). The original antibody was used successfully for blocking the PD-1 pathway in combination with ex vivo TKD/IL-2-stimulated NK cells in preclinical models of glioblastoma and lung cancer. It was found that this combination therapy significantly enhanced the cytotoxic activity of NK cells compared to monotherapy. The treatment resulted in improved overall survival, massive infiltration of tumors by CD8⁺ cytotoxic lymphocytes and NK1.1 cells, and a reduction of PD-1⁺ immune cells in the tumor microenvironment. Additionally, the combined therapy maintained its anti-tumor effects even after discontinuation, suggesting long-term benefits and highlighting the potential of this combined immunotherapeutic approach (Shevtsov et al., 2019; PMID: 30967859). The original version of this antibody was used successfully in an in vitro blocking assay on EL4 cells. It was also used for FC analysis and was found to stain the cells with medium intensity compared to the other tested antibodies (Polesso et al., 2021; PMID: 33684223). This antibody was also used for the FC and FACS analyses on tumor-infiltrating immune cells (TIIs) (Yokota et al., 2021; PMID: 34355173) and murine B16-F10 and YUMM melanoma cells and T-cells subsets (Martins et al., 2022; PMID: 35864188). This antibody was tested for its binding affinity to Jurkat cells expressing mouse PD-1. It exhibited intermediate avidity for PD-1 and showed limited capability to reverse PD-1-mediated T-cell inhibition compared to other tested antibodies. It demonstrated partial epitope blocking against itself and another PD-1 monoclonal antibody, indicating its suitability for specific experimental conditions requiring PD-1 staining alongside functional assessments (Bu et al., 2022; PMID: 35925787).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews